An elderly woman looking off into the distance.
An elderly woman looking off into the distance.

Investor Relations

Investor Relations represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active and transparent investor relations work, the aim is to enable investors to make an informed decision of the Company.

Latest News

09/12/2023

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Read more
Linked InTwitter
08/09/2023

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Read more
Linked InTwitter
08/03/2023

Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Read more
Linked InTwitter
View All

Corporate Presentations and Reports

A grandmother hugging two little girls
A grandmother hugging two little girls

Corporate Presentation

Overview of our business strategy, mid- to late-stage oncology pipeline, financials and investment thesis.  

READ MORE
Non-financial Group Report 2022 Desktop
Annual Report 2022 Mobile

Annual Report 2022

We offer insights into our company, our mission as well as our corporate and financial report, our clinical pipeline and much more.

Read More
A young boy hugging his grandfather
ESG_Report_2022_mobile

Non-Financial Group Report 2022

We provide information on business ethics and compliance as well as social, employee and environmental issues.

Read More

Events & Conferences

15 Nov 2023

Publication of Third Quarter Interim Statement 2023

Virtual Save the date
VIEW ALL EVENTS

INVESTOR INFORMATION

Financial Information

Financial Information

Take a closer look at our Financial Guidance 2023 and the Fundamentals of MorphoSys.

Read more

Annual General Meeting

The virtual Annual General Meeting 2022 of MorphoSys AG.

Read more
Stock

Stock Information

MorphoSys stock information in detail.

Read more

Corporate Governance

We believe that our commitment to high Corporate Governance standards will ultimately increase shareholder value.

Read more
clinical trials
Clinical trials

Our Understanding of Sustainability

We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success.

Read more

Publications

0/0

SEC Filings

Read more

Order form for publications and reports

Get Press Releases (Corporate News, Annual Reports, Quarterly Reports).
Read more

Investor Contact

JNE

DR. JULIA NEUGEBAUER

HEAD OF INVESTOR RELATIONS

Tel. +49 89 89927 179
Julia.Neugebauer@morphosys.com
https://www.linkedin.com/in/julia-neugebauer-48a048b2